tbuckley/cabot-search huggingface dataset:
Circulating endothelial cells as a biological marker for acute toxicity in rectal cancer patients receiving postoperative concurrent chemoradiation
Authors: Yu-Jen Chen, Tzu-Chi Hsu, Chen-Hsi Hsieh
Journal: Clinical Cancer Research (2008)

AACR Centennial Conference: Translational Cancer Medicine-- July 20-23, 2008; Monterey, CA

B11 

Concurrent chemoradiation (CCRT) is now a standard postoperative adjuvant treatment for high-risk rectal cancer patients. However, no surrogate marker for optimization of adjuvant CCRT is available. Circulating endothelial cells (CEC) and endothelial progenitor cells (EPC) were observed to correlate the tumor response after metronomic therapy. This study aimed to examine the feasibility of CEC and/or EPC as a marker for adjuvant CCRT toxicity in rectal cancer. Between November 2006 and April 2008, 11 rectal cancer patients treated with radical proctectomy were enrolled (ClinicalTrials.gov Identifier [NCT00325871][1]). Postoperative RT with concurrent UFT followed by metronomic UFT administration was applied as adjuvant treatment. Peripheral blood was sampled weekly before and during CCRT as well as monthly thereafter. The kinetics of CEC, apoptotic CEC and EPC was estimated by flow cytometry with proper parameters. CCRT toxicity was graded according to version 3.0 of the NCI-CTCAE. At various time points, 6 patients developed grade 3 diarrhea, 1 had grade 2 cystitis, 1 suffered from acute urinary tract infection and 1 experienced peritonitis. In all patients with acute CCRT toxicity, a burst of increase in the amounts of CEC was consistently noted at the time that severest toxicity developed. These changes recovered while symptoms/signs subsided. Neither the EPC nor the white blood cells (WBC) kinetics shows such evident correlation. The amounts of CEC and EPC had no significant correlation with WBC or absolute neutrophil counts. The follow-up CEC kinetics during adjuvant metronomic UFT administration show a recovery trend after completion of RT. Overall, the amounts of CEC declined during CCRT, except that increased while severe toxicity developed, and then resume during adjuvant metronomic therapy. In conclusion, the kinetics of CEC correlates with that of CCRT toxicity. To suggest CEC as a surrogate marker for optimization of CCRT, further validation by clinical investigations is warranted.

 [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00325871&atom=%2Fclincanres%2F14%2F15_Supplement%2FB11.atom
Beauty Through Hygiene. Common Sense Ways to Health for Girls.
Authors: Emma E. Walker, Arabella Kenealy
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Weekly paclitaxel in metastatic angiosarcoma. A FNCLCC French Sarcoma Group (GSF-GETO) phase II trial
Authors: N. Penel, B. Bui Nguyen, J. O. Bay, D. Cupissol, I. Ray-Coquard, S. Piperno-Neumann, P. Kerbrat, C. Fournier, C. Mahier, J. Y. Blay
Journal: Journal of Clinical Oncology (2007)

10002 Background: Angiosarcomas (AS) are unfrequent tumors with aggressive metastatic spreading. Although no prospective clinical trial has been so far specifically dedicated to these advanced tumors, their treatments are usually anthracyclin-based. However, a single institution-based retrospective study has suggested that paclitaxel (P) may have some efficacy in metastatic AS [Fata F et al. Cancer 1999, 86, 2034–7]. The aim of the following phase II study is to prospectively evaluate the efficacy and tolerance of weekly P in metastatic AS. Methods: Eligible patients were as follows: =18 years-old, measurable histologically-proven metastatic AS, and either naïve or pretreated patients (pts). Pts were planned to receive P 80 mg/m 2 on day 1, 8 and 15, every 28 days until progression or severe toxicity. The primary endpoint was the objective response rate after 2 cycles, according to RECIST. A two stages Simon‘s optimal design was used with p 0 =10%, p 1 =30%, a=0.05 and 80% power. Results: From 04/2005 to 10/2006, 30 pts were included in 12 centers. There were 19 female and 11 male, and the mean age was 63 (range 23–85). Main primaries were breast, skin or scalp, liver and kidney in 8, 8, 3 and 2 cases, respectively. 33% (10/30) of these AS occurred in irradiated fields (9 for breast adenocarcinoma). Seventy three per cent of the pts (22/30) had previous surgery and 47% (14/30) previous chemotherapy, including anthracyclin in all cases. The number of pts who received 3, 4, 5 and 6 cycles of P were 15, 11, 6 and 4, respectively. Grade (G) 4 toxicity was reported in 1 case (neutropenia). G2 and 3 toxicities were notified for 27/30 pts including myalgias in 15 cases (55%), leuco-neutropenia in 14 cases (51%), infections in 6 cases (22%), and anemia in 4 cases (15%). As of 12/2006, 23 pts were evaluable for response, with 4 (14%) PR, 14 (56%) SD and 7 (30%) PD. The overall tumor- control rate (PR+SD) was 16/23 (70% (95% CI:50–88%). Conclusions: Weekly paclitaxel induces a significant tumor control with manageable toxicity for metastatic AS. No significant financial relationships to disclose.
Yield of Downstream Tests After Exercise Treadmill Testing
Authors: Mitalee P. Christman, Marcio Sommer Bittencourt, Edward Hulten, Ekta Saksena, Jon Hainer, Hicham Skali, Raymond Y. Kwong, Daniel E. Forman, Sharmila Dorbala, Patrick T. O'Gara, Marcelo F. Di Carli, Ron Blankstein
Journal: Journal of the American College of Cardiology (2014)
Abstract 4423: The AGELESS Study: The Effect of Aliskiren vs Ramipril Alone or in Combination with Hydrochlorothiazide and Amlodipine in Patients ≥ 65 Years of Age with Systolic Hypertension
Authors: Daniel A Duprez, Pamela Davis, Jaco Botha
Journal: Circulation (2008)

Background: Indirect renin-angiotensin blockade by ACE-inhibition has shown to be effective in lowering blood pressure (BP) in the elderly hypertensive patient. In contrast, the benefits of direct renin inhibition (DRI) on BP has not been extensively studied in an older hypertensive population. Aim of the study: The primary aim was to demonstrate non-inferiority between the DRI, aliskiren and ACE-I, ramipril on the change from baseline in systolic BP (SBP) after 12 weeks (w) of treatment with monotherapy among patients ≥ 65 years of age. If non-inferiority was demonstrated, then an analysis for superiority of aliskiren compared with ramipril would be conducted. The secondary aim was to compare aliskiren-based therapy to ramipril-based therapy after 36 w on SBP. Methods: In this double-blind parallel multi-center study, hypertensive patients with an age ≥ 65 years with a SBP ≥ 160 mmHg either untreated or after a wash-out period were randomized either to aliskiren 150 mg/day or ramipril 5 mg/day for 4 w. If SBP was not at goal at 4 w (&lt; 140 mmHg), study medication doses were doubled to aliskerin 300 mg/day or ramipril 10 mg/day and SBP was evaluated at 12 w. If SBP was not at goal (&lt;140 mmHg), HCTZ (12.5 → 25mg/day) followed by amlodipine (5→10mg/day) regimen were added and SBP was evaluated at 36 w. In the aliskiren group, 457 patients with a mean age of 72.0 years, (51 % females) and in the ramipril group 444 patients with a mean age of 72.2 years, (53 % females) were enrolled. Patients ≥ 75 years of age made up 32.5% of the total population. Results : Table 1 summarizes the results. Conclusion: In an elderly population with systolic hypertension, DRI monotherapy with aliskiren provided a greater reduction in SBP than ramipril after 12 w of treatment and was well tolerated. After 36 w an aliskiren-based regimen provided similar SBP lowering efficacy, compared with a ramipril-based regimen. The incidence of adverse and serious events was similar between the two groups. Table 1: Change from baseline in SBP at week 12 and 36 between the Aliskiren and Ramipril group
Association of germline polymorphisms in genes involved in the CD44 pathway and clinical outcome in localized gastric adenocarcinoma (GA).
Authors: Y. Ning, T. Winder, D. G. Power, D. Yang, W. Zhang, P. O. Bohanes, G. Lurje, L. H. Tang, M. A. Shah, H. Lenz
Journal: Journal of Clinical Oncology (2010)

4047 Background: CD44 is a transmembrane glycoprotein serving as receptor of hyaluronan and osteopontin, is associated with adhesion and metastasis in gastrointestinal carcinomas. Moreover, a gastric cancer stem cell population with CD44 as their defined surface marker has been identified showing increased resistance for chemotherapy- or radiation-induced cell death. High CD44 protein expression has been associated with poor prognosis in GA. We tested the hypothesis whether germline variations involved in the CD44 pathway will predict clinical outcome in patients with localized GA. Methods: Either blood or FFPE tissues specimens were obtained from 137 patients (54 females and 83 males; median age = 55 yrs; range = 21-85 yrs) with localized GA at University of Southern California (n = 105) and Memorial Sloan-Kettering Cancer Center medical facilities (n = 32). The median follow-up was 3.3 years. Sixty-one of 137 patients (45%) had tumor recurrence, with a probability of 3-year recurrence of 52%. Genomic DNA was isolated from peripheral blood or FFPE tissues and germline variants within the CD44 (rs8193, rs187116, rs4755392, rs7116432), osteopontin (rs9138, rs1126616) and hyaluronan (rs4123220, rs1057308) genes were determined by PCR-RFLP technique. Results: The G allele (GG; AG) at the CD44 +4883G>A gene locus (rs187116) and the A allele (AA; AG) at the CD44 +779G>A gene locus (rs7116432) had a significantly shorter median TTR of 2.1 years compared to 7.0 years (p = 0.036, log-rank test) and a median OS of 2.2 years compared to 7.0 years (p = 0.045, log-rank test), respectively in univariate analysis. After adjusting for clinical parameters, patients harboring 0 favorable alleles of the tested CD44 SNPs had a significantly worse TTR (RR: 2.41; adjusted p value = 0.016) and OS (RR: 2.74; adjusted p value = 0.019) in the multivariable analysis. No statistical significant association was found between TTR or OS and the other tested germline variants. Conclusions: For the first time, this study identified germline variants within the CD44 gene as independent prognostic markers in localized GA. Our exploratory data warrant future confirmatory trials. No significant financial relationships to disclose.
Le bactériophage et son comportement.
Authors: Felix d'. Hérelle
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correspondence re: Giovanna Caderni et al., Effect of Dietary Carbohydrates on the Growth of Dysplastic Crypt Foci in the Colon of Rats Treated with 1,2-Dimethylhydrazine. Cancer Res., 51: 3721–3725, 1991—Reply
Authors: Piero Dolara, Giovanna Caderni
Journal: Cancer Research (1992)
Health bodies resign from "charade" of EU alcohol forum
Authors: J. Wise
Journal: BMJ (2015)

More than 20 public health organisations have resigned from the European Union’s Alcohol and Health Forum after expressing deep concern that the interests of the alcohol industry have been prioritised over public health.

The forum includes representatives from the alcohol industry, as well as public health experts and non-governmental organisations. In an open letter to the EU commissioner for health and food safety, Vytenis Andriukaitis, the signatories expressed their deep concern over a lack of plans to develop a comprehensive European alcohol strategy …
Disagreement in pathology: Impact in clinical decision-making
Authors: E. Gil Deza, H. Japaze, J. Emina, C. Díaz, M. Abal, C. García Gerardi, J. Novelli, E. Morgenfeld, E. Rivarola, F. G. Gercovich
Journal: Journal of Clinical Oncology (2005)

6077 Background: The IOHM is an ambulatory cancer center where patients are referred after the diagnosis of cancer is certified elsewhere. From 1997 onwards, all our patients have their pathological diagnosis reviewed in order to assure high clinical quality standards. The pathology files include more than 5000 cases handled according to the recommendations of the Association of Directors of Anatomic and Surgical Pathology of America and the Argentinian Society of Pathology. The aim of this study is to investigate the discrepancies that occurred in the pathology review and their potential clinico-therapeutic implications. Methods: Review of pathology reports of 637 cases of breast cancer on the pathological files of our institution was performed. All cases were analyzed initially by an external pathologist who established the diagnosis and after referral to our center by either two independent pathologists for in-house review. Discrepancy in pathological diagnosis (DPD) were categorized as: DPD 0= No discrepancy, DPD-I= discrepancy about the malignant nature of the tumor, DPD-II: discrepancy in tumor infiltration (in situ vs infiltrating), DPD-III: discrepancy in histological type (lobulillar vs ductal) and DPD-IV: discrepancy in histological subtype. Results: The following discrepancies were observed: DPD-0: 365/637 (57%), DPD-I: 9/637 (1.4%), DPD-II: 23/637 (3.6%), DPD-III: 45/637 (7%), DPD-IV: 195/637 (31%). Conclusions: Severe DPD (I and II) were observed in one case every twenty. Major discrepancies in histological type seen in 7% of the cases and about 30% can be further subtyped after expert pathology revision. The revision of pathology diagnosis by an expert board is essential to assure quality of patient care and for malpractice prevention. No significant financial relationships to disclose.
Primary gastroenteropancreatic poorly differentiated neuroendocrine carcinoma: Clinico-pathologic analysis of 68 cases
Authors: M. H. Bukhari, E. Byron, J. R. Strosberg, N. A. Nasir, E. Henderson-Jackson, M. Bui, A. Hakam, C. Domenico, L. Kvols, A. Nasir
Journal: Journal of Clinical Oncology (2009)

e15616 Background: Primary gastro-entero-pancreatic poorly differentiated neuroendocrine carcinomas (GEP-PDNECAs) are highly aggressive neoplasms with a very poor prognosis. This study was conducted to evaluate the immuno-morphological spectrum of GEP-PDNECA, and patient survival with systemic platinum and etoposide therapy. Methods: Under an IRB-approved protocol, clinico-pathologic data were collected on 68 adult patients with GEP-PDNECA who had undergone biopsy / resection at MCC or outside institution. Data sources: Pathology archives, consultation files, tumor registry and social security index. All available slides were reviewed and tumors were histologically sub-typed. Subsequently, clinico-pathologic data and patient survival were analyzed. Results: Patients: 41 M/27 F. Age: 25–76 yrs (mean 42 yrs). Sites: Colo-rectum 39, pancreas 19, small intestine (SI) 4, stomach 3, colon/SI/pancreas 3. 63 of 68 (93%) patients presented with lymph node/distant metastases. Of 68 tumors 37 (54%) were classified as small cell carcinoma (SCCA), 16 (24%) large cell carcinoma (LCCA), 5 (7%) mixed small and large cell (MSLCCA) and 10 (15%) poorly differentiated carcinoma with neuroendocrine features (PDCA-NEF). Tumors were positive for chromogranin in 38/65 (55%), synaptophysin in 62/67 (92%), and CD56 in 17/21 (81%) cases. One marker was positive in 22/68 (32%), 2 in 40/68 (59%) and all 3 were positive in 9/68 (13%) cases. Fifty eight of 68 (85%) patients were treated with platinum and etoposide. Overall survival at 1, 3 and 5 years was 85%, 40% and 24% respectively. Patient survival was independent of age (r= -0.1022), sex (r= -0.909) and histologic subtype (r= - 0.1028) (p= 0.128) but was related to distant metastases (r=0.306; p=0.0383). Conclusions: Diagnosis of GEP-PDNECA can be based on histo-morphologic features and expression of neuroendocrine markers. Synaptophysin was the most sensitive marker; however, a panel of 2 or 3 neuroendocrine markers (Syn, Cg and CD56) may be more useful to avoid under-diagnosis of GEP-PDNECA, especially in the metastatic setting. Although survival of GEP-PDNECA patients following platinum and etoposide in our series was relatively favorable, there is need for novel therapies to improve patient survival. No significant financial relationships to disclose.
Safety of erythropoetin administration in first-line chemotherapy of ovarian carcinoma: Results of a prospective study
Authors: A. Mustea, G. Oskay-Oezcelik, H. L. Sommer, E. Keil, M. Höckel, J. Pfisterer, O. Camara, H. Hindenburg, W. Lichtenegger, J. Sehouli
Journal: Journal of Clinical Oncology (2008)

16574
Outpatient psychotherapy in the United States, I: Volume, costs, and user characteristics
Authors: M Olfson, H A Pincus
Journal: American Journal of Psychiatry (1994)

This article provides an overview of the volume, composition, and costs of outpatient psychotherapy in the United States.Data were analyzed from the household section of the 1987 National Medical Expenditure Survey. The authors determined the volume and distribution of psychotherapy visits by provider specialty, setting, source of expenditure, and reason for visit. An examination was made of the demographic characteristics, health status, and mental health utilization profile of psychotherapy users.In 1987, Americans made 79.5 million outpatient psychotherapy visits at a total cost of $4.2 billion. Most of these visits were to mental health specialists (more than 80%) and were reported to be for the treatment of mental health conditions (63.5%). However, psychotherapy was not provided in a substantial proportion of the visits to mental health specialists (21.1%) or the visits to treat mental conditions (29.8%). Separated and divorced persons, females, whites persons aged 35 to 49 years, and those with more than 15 years of education had a greater likelihood of using psychotherapy. Psychotherapy use was also greater among persons in poor general health and those reporting health-related functional impairments. General medical costs of psychotherapy users exceeded those of nonusers.Psychotherapy accounts for approximately 8% of outpatient medical care costs. Users of psychotherapy appear to be more distressed than is commonly assumed: they report poorer general health, higher general medical costs, and more functional impairment than nonusers. Although mental health specialists commonly provide psychotherapy to treat mental disorders, all mental health care is not psychotherapy.
Progress toward achieving a common language in psychiatry, II: Results from the international field trials of the ICD-10 diagnostic criteria for research for mental and behavioral disorders
Authors: N Sartorius, T B Ustün, A Korten, J E Cooper, J van Drimmelen
Journal: American Journal of Psychiatry (1995)

In preparing for the publication of ICD-10, the Division of Mental Health of the World Health Organization developed several versions of chapter V, which deals with mental and behavioral disorders. The version for research purposes is called the Diagnostic Criteria for Research (ICD-10 DCR) and gives operational criteria for the diagnosis of mental disorders. This article describes the results of international field trials undertaken to evaluate the draft criteria and refine them further.Data were obtained to assess interrater agreement, the confidence with which diagnoses could be made, and the ease of use of the criteria. Additional substudies examined the concordance between ICD-10 DCR, ICD-10 Clinical Descriptions and Diagnostic Guidelines, and other national classification systems (e.g., DSM-IV). The field trials were carried out at 151 clinical centers in 32 countries by 942 clinician/researchers who conducted 11,491 individual assessments of patients. Results for cases assessed by at least two raters are reported here.Most clinician/researchers found the criteria to be explicit and easy to apply. Interrater agreement was high for most diagnostic categories. For some categories, such as those dealing with certain polymorphic psychotic disorders or milder forms of affective disorders, the criteria were rated as somewhat difficult to use, and reliability was lower. Comparison of the results of these field trials with those of the ICD-10 Clinical Descriptions and Diagnostic Guidelines demonstrated that there are increases in interrater agreement when the operational criteria are used.The use of internationally accepted research criteria enhances the reliability of diagnosis of mental disorders made in research settings worldwide.
Corpuscles. Atlas of Red Blood Cell Shapes.
Authors: Marcel Bessis
Journal: Annals of Internal Medicine (1975)

On the Beauty of the Red Cell.- On the Beauty of the Red Cell.- On Nomenclature.- On Nomenclature.- The Normal Red Cell.- I Red Cell Birth.- II Discocytes.- Experimental Manipulations.- III Echinocytes.- IV Stomatocytes.- Pathological Shapes.- V Drepanocytes.- VI Echino-Drepanocytes and Stomato-Drepanocytes.- VII Keratocytes and Schizocytes.- VIII Dacryocytes.- IX Codocytes and Target Cells.- X Spherocytes and Knizocytes.- XI Elliptocytes.- XII Acanthocytes.- Interlude.- XIII Zoo.- Senescence and Death.- XIV Micro-spherulation.- XV Hemolysis.- XVI Red Cell Death.- Technique.